

# The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

Esther Zipperer, Daniela Pelz, Kathrin Nachtkamp, Andrea Kuendgen, Corinna Strupp, Norbert Gattermann, Rainer Haas, and Ulrich Germing

Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany

Citation: Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N, Haas R, and Germing U. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. *Haematologica* 2009; doi:10.3324/haematol.2008.002063

**Online Supplementary Table S1. The Charlson Comorbidity Index.**

Comorbidities	Score
Myocardial infarction	1
Congestive heart failure	1
Peripheral vascular disease	1
Cerebrovascular disease	1
Dementia	1
Chronic pulmonary disease	1
Connective tissue disease	1
Ulcer disease	1
Mild liver disease	1
Diabetes (without complications)	1
Diabetes with end organ damage	2
Hemiplegia	2
Moderate or severe renal disease	2
2nd solid tumor (non metastatic)	2
Leukemia	2
Lymphoma, Multiple Myeloma	2
Moderate or severe liver disease	3
2nd metastatic solid tumor	6
AIDS	6

**Online Supplementary Table S2. HCTCI score.**

Comorbidities	Score
Arrhythmia	1
Cardiac disease	1
Inflammatory bowel disease	1
Diabetes mellitus	1
Cerebrovascular disease	1
Psychiatric disturbance	1
Hepatic, disease, mild	1
Obesity	1
Infection	1
Rheumatologic disease	2
Peptic ulcer	2
Moderate/severe renal disease	2
Moderate pulmonary disease	2
Prior solid malignancy	3
Heart valve disease	3
Severe pulmonary disease	3
Moderate/severe hepatic disease	3